Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 3/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 17/20 | 0.69 |
| ▸ | SLC6A2 | P23975 | 15/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 13/20 | 0.69 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13950721 | 1.00 | SLC22A1 (0.72) | SLC22A1SLC6A4SLC6A2OPRM1OPRD1 | |
| SCHEMBL15216759 | 0.85 | SLC6A4 (0.74) | SLC22A1SLC6A4SLC6A2OPRM1OPRD1 | |
| SCHEMBL12298854 | 0.85 | SLC6A4 (0.74) | SLC22A1SLC6A4SLC6A2OPRM1OPRD1 | |
| SCHEMBL13292259 | 0.85 | SLC6A4 (0.74) | SLC22A1SLC6A4SLC6A2OPRM1OPRD1 | |
| SCHEMBL28739214 | 0.85 | SLC22A1 (0.68) | SLC22A1SLC6A4SLC6A2OPRM1OPRD1 | |
| SCHEMBL4393889 | 0.84 | SLC22A1 (1.00) | SLC22A1SLC6A4SLC6A2OPRM1OPRD1 | |
| SCHEMBL13942259 | 0.84 | SLC22A1 (1.00) | SLC22A1SLC6A4SLC6A2OPRM1OPRD1 | |
| SCHEMBL4393885 | 0.84 | SLC22A1 (1.00) | SLC22A1SLC6A4SLC6A2OPRM1OPRD1 | |
| SCHEMBL4393890 | 0.84 | SLC22A1 (1.00) | SLC22A1SLC6A4SLC6A2OPRM1OPRD1 | |
| SCHEMBL14532254 | 0.84 | SLC22A1 (1.00) | SLC22A1SLC6A4SLC6A2OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3296289-A2 | PHENYL SUBSTITUTED CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | Sunovion Pharmaceuticals Inc. (US) | 2018-03-21 | — | — | EP | disclosed |
| US-20170204050-A1 | PHENYL SUBSTITUTED CYCLOALKYLAMINES AS MONOAMINE REPUTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170204050-A1 | PHENYL SUBSTITUTED CYCLOALKYLAMINES AS MONOAMINE REPUTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2017-07-20 | — | — | US | disclosed |
| US-9586888-B2 | Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586888-B2 | Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20140121282-A1 | PHENYL SUBSTITUTED CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-20140121282-A1 | PHENYL SUBSTITUTED CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8669291-B2 | Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669291-B2 | Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2014-03-11 | — | — | US | disclosed |
| EP-2617704-A1 | Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors | Sepracor Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20090005456-A1 | PHENYL SUBSTITUTED CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SEPRACOR INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005456-A1 | PHENYL SUBSTITUTED CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SEPRACOR INC. (US) | 2009-01-01 | — | — | US | disclosed |
| WO-2008151156-A1 | PHENYL SUBSTITUTED CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SEPRACOR INC. (US) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005456-A1 | PHENYL SUBSTITUTED CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | SLC22A1 443/4885SLC6A4 4/4885SLC6A2 2/4885 |
| US-20140121282-A1 | PHENYL SUBSTITUTED CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | SLC22A1 443/4885SLC6A4 4/4885SLC6A2 2/4885 |
| US-20170204050-A1 | PHENYL SUBSTITUTED CYCLOALKYLAMINES AS MONOAMINE REPUTAKE INHIBITORS | SLC18A2, SLC18A3, SLC6A2 | SLC22A1 625/4885SLC6A4 4/4885SLC6A2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.